Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (11-20 of 164) with videos related to

Pageof 17
Sort By:
Annales De Pathologie|August 12, 2003
[An uncommon and misleading neoplasm to know!]Guillaume Granier, Pierre Feugier, Cyrille Hulin, et al.
Leukemia & Lymphoma|August 23, 2011
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Eric Van Den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, et al.
Experimental Hematology|February 21, 2007
Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacityNa Li, Pierre Feugier, Brigitte Serrurrier, et al.
Clinical Case Reports|September 28, 2020
Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet countMarion Divoux, Alexia Plocque, Margaux Sevin, et al.
Journal of Clinical Medicine|November 11, 2022
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin LymphomaEsther Hazane Leroyer, Caroline Ziegler, Charline Moulin, et al.
Frontiers in Immunology|December 31, 2020
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter SyndromeHélène Augé, Anne-Béatrice Notarantonio, Romain Morizot, et al.
Annales De Biologie Clinique|February 4, 2022
[Investigation of large granular lymphocytic leukemias: data from the laboratory of hematology at Nancy University Hospital, France]Charles Guisnel, Jean-François Lesesve, Delphine Gérard, et al.
Leukemia & Lymphoma|April 6, 2011
Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplantNatacha Heutte, Corinne Haioun, Pierre Feugier, et al.
Journal of Hematotherapy & Stem Cell Research|February 16, 2002
Ex vivo expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34+ cells on human endothelium transfected with adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligandPierre Feugier, Deog Yeon Jo, Jae Hung Shieh, et al.
Cancers|August 10, 2024
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final AnalysisMarie Maerevoet, Olivier Casasnovas, Guillaume Cartron, et al.
Pageof 17

Showing results (11-20 of 164) with videos related to

Sort By:
Pageof 17
Annales De Pathologie|August 12, 2003
[An uncommon and misleading neoplasm to know!]Guillaume Granier, Pierre Feugier, Cyrille Hulin, et al.
Leukemia & Lymphoma|August 23, 2011
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Eric Van Den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, et al.
Experimental Hematology|February 21, 2007
Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacityNa Li, Pierre Feugier, Brigitte Serrurrier, et al.
Clinical Case Reports|September 28, 2020
Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet countMarion Divoux, Alexia Plocque, Margaux Sevin, et al.
Journal of Clinical Medicine|November 11, 2022
Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin LymphomaEsther Hazane Leroyer, Caroline Ziegler, Charline Moulin, et al.
Frontiers in Immunology|December 31, 2020
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter SyndromeHélène Augé, Anne-Béatrice Notarantonio, Romain Morizot, et al.
Annales De Biologie Clinique|February 4, 2022
[Investigation of large granular lymphocytic leukemias: data from the laboratory of hematology at Nancy University Hospital, France]Charles Guisnel, Jean-François Lesesve, Delphine Gérard, et al.
Leukemia & Lymphoma|April 6, 2011
Quality of life in 269 patients with poor-risk diffuse large B-cell lymphoma treated with rituximab versus observation after autologous stem cell transplantNatacha Heutte, Corinne Haioun, Pierre Feugier, et al.
Journal of Hematotherapy & Stem Cell Research|February 16, 2002
Ex vivo expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34+ cells on human endothelium transfected with adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligandPierre Feugier, Deog Yeon Jo, Jae Hung Shieh, et al.
Cancers|August 10, 2024
Phase IB Study of Oral Selinexor in Combination with Rituximab and Platinum Chemotherapy in Patients with Relapsed/Refractory B-Cell Lymphoma-Final AnalysisMarie Maerevoet, Olivier Casasnovas, Guillaume Cartron, et al.
Pageof 17